We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Bristol Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Each day, our employees around the world work together for patients - it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, hematology, cardiovascular, and immunology. Through our Research & Development organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.
As global citizens, we work sustainably and responsibly and seek to give back. Through the Bristol Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
About Bristol Myers Squibb in Belgium
To all those working tirelessly in the fight against COVID-19, you inspire us to do our part. At Bristol Myers Squibb we are here to continue to support and do all we can for patients, and for those affected by the pandemic. All healthcare professionals, caregivers, volunteers and service providers are on the frontline against an invisible enemy.
From the bottom of our hearts: Thank you.
We're proud to help our BMS employees volunteering in the fight against this disease.
Please read the inspiring story of our colleague Patrick Lamotte, volunteering in a nursing home in Brussels.
In Braine-l'Alleud, a stone's throw away from Brussels, Bristol Myers Squibb in Belgium hosts different divisions including commercial, sales and marketing. It serves as a hub for BMS European and global R&D divisions.
The European and global Research & Development hub hosts the European Regulatory, Safety and Biostatistics departments and Global Clinical Operations. Every day medical scientists are working tirelessly on the development of new treatments in the area of oncology, hematology, cardiovascular, and immunology.
Pioneer and leader in immunotherapy
Bristol Myers Squibb is a pioneer and leader in immunotherapy. 2017 marked the 5-year anniversary of ipilimumab in Belgium, the first immunotherapy for melanoma to hit the market both in Belgium and globally. Apart from that, it has taken only two years for nivolumab, the second-generation immunotherapy, to be approved by the European Commission. Today nivolumab (Opdivo) is reimbursed in Belgium for eight indications in six distinct tumor types, making Belgium one of the fastest approval markets in Europe.
A clear ambition to tackle societal healthcare challenges
The ambition of Bristol Myers Squibb Belgium is clear: it wants to tackle societal healthcare challenges within Belgium through education and through facilitating changes in the healthcare system. Bristol Myers Squibb Belgium wants to help create an environment in which a debate with the healthcare community can take place, to anticipate key future issues, through for instance educating healthcare professionals in immuno-therapy, or supporting newly emerging healthcare professions.
A common passion: saving and improving patients' lives
At the heart of Bristol Myers Squibb Belgium lies an informal and lean culture, focused on respect for people and an entrepreneurial spirit. Employees all share the same passion, saving and improving patients' lives and are encouraged to take initiatives to embrace a healthy lifestyle and support causes close to the company’s mission.
Corporate Social Responsibility
Over several years, Bristol Myers Squibb has been launching the Country 2 Country 4 Cancer Ride (C2C4C). This epic cycling event supports the Union for International Cancer Control (UICC) and a number of local charity members to increase awareness and amplify fundraising efforts. In 2017 and 2018, the Benelux team chose to support the European Cancer Patient Coalition (ECPC) in its mission to be the voice of cancer patients across Europe. From September 10th to September 27th 2018, six teams totaling 80 riders have committed to going the distance in this year’s ride, which covers approximately 4000 kilometers. The ride was kicked off in Germany (Munich) and drove via Switzerland, Italy, France and Spain, to France again. The Benelux team finalized the last segment from Tours to Uxbridge.
BMS riders are motivated by a unifying purpose: helping cancer patients to be able to create and share more treasured memories with those they love. Money raised is matched by Bristol Myers Squibb, doubling the impact of the generosity of the contributors.
BMS has already committed to hold the Country 2 Country 4 Cancer ride for the next 3 years!
Our Bristol Myers Squibb values and principles commit us to the highest standard of moral and ethical behavior and affirms our conviction that "the priceless ingredient of every product is the honor and integrity of its maker."
The Bristol Myers Squibb Foundation promotes health equity and seeks to improve the health outcomes of populations disproportionately affected by serious diseases. The Bristol Myers Squibb Foundation has a number of Global Initiatives & Programs.
Our company is guided by a Leadership Team that brings a rich and diverse set of experience to navigate an evolving and fast-paced global healthcare landscape. We deliver on our commitments: to our patients and customers, to our employees, to our global communities, to our shareholders, and to our environment. Ultimately, our success will be measured by the difference we can make in the lives of patients. The Leadership Team is responsible for the day-to-day operation of the company.